WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
WuXi XDC Announces Ground-breaking on Singapore Manufacturing Facility to Empower Global Bioconjugates Development
Shanghai, China, and Singapore, March 19, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugates market, today announced a ground-breaking of manufacturing...WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan 31, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for...
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
Shanghai, China, and Incheon, South Korea, Jan.24, 2024—WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading...WuXi XDC Congratulates OnCusp Therapeutics on Series A Financing to Expedite Portfolio of Assets for Cancer Patients
Shanghai, January 15th, 2024 – WuXi XDC（2268.HK）, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) focused on ADC and other types of bioconjugates market, congratulates OnCusp Therapeutics on the completion of $100 million Series A...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?